Tuberous sclerosis complex 1 (TSC1) and TSC2 are suppressors of mechanistic target of rapamycin (mTOR). mTOR is the major component of two protein complexes: mTOR complex 1 (mTORC1) and mTORC2. Inactive mutation of either TSC1 or TSC2 unleashes mTOR signaling and consequently causes TSC, a benign tumor syndrome affecting multiple organs. We report here that expression of aB-crystallin was upregulated in Tsc1 À / À or Tsc2 À / À mouse embryonic fibroblasts, Eker rat uterine leiomyoma-derived Tsc2-deficient ELT3 cells, mutant Tsc2-associated mouse kidney tumors, and human lung lymphangioleiomyomatosis nodules. aB-crystallin was transcriptionally activated by mTOR complex 2 (mTORC2): nuclear factor-kappa B (NFkB) signaling cascade. The augmented aB-crystallin was critical for the migration, invasion and apoptotic resistance of Tsc2-defective cells. Disruption of aB-crystallin suppressed Tsc2-null cell proliferation and tumorigenesis. Therefore, enhanced aB-crystallin has an essential role in TSC1/2 complex deficiency-mediated tumorigenesis, and inhibition of aB-crystallin may complement the current therapy for TSC.
INTRODUCTION
The receptor tyrosine kinase/phosphatidylinositol 3-kinase/AKT/ mechanistic target of rapamycin (RTK/PI3K/AKT/mTOR) signaling cascade, which has pivotal roles in cell metabolism, autophagy, growth, proliferation and survival, is one of the most frequently deregulated signaling pathways in cancers. [1] [2] [3] [4] The constitutive activation of this network is often caused by gain-of-function mutations of proto-oncogenes, such as epidermal growth factor receptor (EGFR), PI3K and AKT, and by loss-of-function mutations of tumor suppressors, such as phosphatase and tensin homolog (PTEN), tuberous sclerosis complex 1 (TSC1) and TSC2. [5] [6] [7] [8] As the major effector of this pathway, mTOR can integrate signals from growth factors, nutrients and energy supplies, and then regulate a subset of gene expression and protein synthesis/modification in controlling cell growth, proliferation and survival. 9 Being a serine/ threonine kinase, mTOR is the catalytic subunit of two distinct complexes named mTOR complex 1 (mTORC1) and mTORC2. 10 mTORC1 consists of mTOR, mLST8, Raptor and PRAS40 11, 12 and controls cell growth and proliferation by modulating mRNA translation through phosphorylation of eukaryotic translation initiation factor 4E binding protein (4E-BP) and ribosomal protein S6 kinase (S6K).
13 mTORC2 contains mTOR, mLST8, Rictor and SIN1 and regulates actin cytoskeleton dynamics. 14 In contrast to the well-documented mTORC1, the function and mechanism of mTORC2 are less characterized.
TSC1 and TSC2 tumor suppressors form a protein complex in suppression of mTOR. mTOR hyperactivation due to inactive mutation of one of these two genes is the major cause for TSC, a benign tumor syndrome afflicting multiple organs. 5, [15] [16] [17] [18] TSC is featured with cerebral cortical tubers, subependymal nodules, renal angiomyolipomas, pulmonary lymphangiomyomatosis (LAM), cardiac rhabdomyomas and facial angiofibroma. 19 LAM is characterized by the abnormal proliferation of smooth muscle-like cells and cystic lung destruction. It is thought to be initiated by histologically benign cells carrying TSC1 or TSC2 mutations that migrated from renal angiomyolipomas. 20, 21 In early 1990s, aB-crystallin had been found elevated in TSC lesions, including the brain, kidney, lung and heart. 22, 23 The putative role of enhanced aB-crystallin in inactive TSC1/2 complex-mediated tumorigenesis is unknown. Besides being a major component in eye lens, aB-crystallin is a ubiquitous small heat-shock protein (sHSP) and can be induced by stress in counteracting the deleterious aggregation of misfolded proteins and thus helping cell survival. 24 Another cytoprotective function of aB-crystallin is antiapoptotic effect. aB-crystallin overexpression can protect cells from apoptosis induced by a large panel of stimuli, whereas aB-crystallin deficiency sensitizes cells to apoptosis. 25, 26 Overexpression of aB-crystallin has also been detected in several human cancers. [27] [28] [29] In this study, we investigated the significance of augmented aB-crystallin in TSC1/2 deficiency-induced tumorigenesis. We found that TSC1 and TSC2 were negative regulators of aB-crystallin expression, and the upregulation of aB-crystallin was mTORC2 dependent. We then identified NFkB as the transducer 1 of mTORC2 upregulation of aB-crystallin. Disruption of aB-crystallin suppressed the cell proliferation and tumorigenesis caused by TSC1/2 deficiency.
RESULTS AND DISCUSSION mTORC2 positively regulates aB-crystallin expression in TSC TSC is featured with tumor lesions in multiple organs. aB-crystallin has been found to be highly expressed in TSC lesions. Therefore, we hypothesized that loss of TSC1/TSC2 complex promoted aberrant cell proliferation through induction of aB-crystallin expression. We found that both aB-crystallin mRNA and protein were markedly elevated in mouse embryonic fibroblasts (MEFs) with mTOR hyperactivation caused by lack of either Tsc1 or Tsc2 gene (Figures 1a and b) , indicating that the upregulation of aB-crystallin expression occurs at the transcriptional level. Mouse kidney tumors with hyperactive mTOR due to loss of heterozygosity for the wild-type Tsc2 allele in Tsc2 þ / À mice 17 exhibited enhanced Table 1) , we found VEGFD (a marker of mTOR activation in LAM) 30 and aB-crystallin were significantly increased in LAM nodules (Table 1) . Taken together, these results demonstrate that TSC1/TSC2 complex negatively regulates aB-crystallin expression both in vitro and in vivo.
mTOR exists in two multiprotein complexes, rapamycinsensitive mTORC1 and rapamycin-insensitive mTORC2. 10 Because loss of TSC1 or TSC2 induces both mTOR hyperactivation and aB-crystallin overexpression, we speculated that mTOR was a positive regulator of aB-crystallin expression. To elucidate which mTOR complex is responsible for the upregulation of aB-crystallin, we first evaluated the effect of rapamycin on aB-crystallin expression. Rapamycin treatment led to marked reduction in S6 phosphorylation (a marker of mTORC1 activity), but no reduction in aB-crystallin expression in WT MEFs, Tsc2 À / À MEFs or rat uterine leiomyoma-derived Tsc2-null ELT3 cells (Figure 1d ). 31 We also treated these cells with WYE-354, an ATP-competitive mTOR kinase inhibitor that could suppress both mTORC1 and mTORC2 activities.
32 WYE-354 markedly reduced aB-crystallin expression in all of these cells (Figure 1d ). Then we cloned a 2193-bp fragment of mouse aB-crystallin gene to luciferase reporter plasmid ( Figure 2d ) and found that the augmented aB-crystallin promoter activity in Tsc2 À / À MEFs was significantly suppressed with WYE-354 treatment, whereas rapamycin treatment did not alter aB-crystallin promoter activity (Supplementary Figures 1a and b) . Furthermore, we knocked down mTOR, rictor or raptor, respectively, in Tsc2 À / À MEFs and ELT3 cells. Reduction in mTOR or rictor significantly decreased aB-crystallin (Figures 1e and f) , whereas reduced raptor did not alter the level of aB-crystallin (Figure 1g) . Consistently, knockdown of rictor, but not raptor, Figures 1c  and d ). Taken together, mTORC2 activates aB-crystallin expression in TSC1/2-deficient cells. It has been reported that mTORC2 has an essential role in TSC2-null cell growth and survival. 33 As aB-crystallin is a downstream target of mTORC2, aB-crystallin may be targeted for the treatment of TSC and other hyperactive mTOR-mediated cancers. mTORC2 stimulates aB-crystallin expression through induction of NFkB NFkB is a key transcriptional factor that regulates expression of a large number of genes involved in apoptosis, proliferation, tumorigenesis and metastasis. 34 The cross talk between PI3K-AKT-mTOR and NFkB signaling cascade has been extensively studied. 35, 36 NFkB activity may be potentiated by both mTORC1 and mTORC2. [37] [38] [39] NFkB signaling was enhanced in Tsc2 À / À MEF cells (Figure 2a) . The augmented signaling was suppressed with inhibition of either mTORC1 by raptor knockdown or rapamycin treatment or mTORC2 by rictor knockdown in both Tsc2 À / À MEFs and ELT3 cells (Supplementary Figure 2 and Figure 2b ). Therefore, similar to mTOR and mLST8, NFkB signaling is a component of both mTORC1 signaling cascade and mTORC2 signaling network in the cells.
As aB-crystallin was upregulated at transcriptional level in mTOR-activated cells, we tested the potential role of NFkB in regulation of aB-crystallin expression. Knockdown of NFkB markedly reduced aB-crystallin expression (Figure 2c ). To investigate whether NFkB transactivates aB-crystallin expression, we identified two putative NFkB-binding sites within the promoter region on mouse aB-crystallin gene (Figure 2d ). Luciferase reporter assay in HEK293T cells showed that overexpression of p65 markedly enhanced the transcriptional activity of the aB-crystallin promoter (Figure 2e) . Moreover, aB-crystallin promoter activity in Tsc2 À / À MEFs was markedly attenuated when either one of its putative NFkB-binding sites was mutated (Figure 2f) . Collectively, these results demonstrate that mTORC2-NFkB axis transactivates aB-crystallin gene expression. As aB-crystallin can suppress the NFkB pathway in astrocytes following TNF stimulation, 40 the negative feedback regulation of NFkB on aB-crystallin may partially contribute to the benign nature of TSC-associated tumor.
Essential role of aB-crystallin for Tsc2-null cells in resistant to serum deprivation-induced apoptosis It has been reported that TSC1/2 deficiency exerts resistance to serum deprivation-induced apoptosis. 41 As both aB-crystallin and loss of TSC1/2 inhibit apoptosis, we postulated that loss of TSC1/2 abrogated serum withdrawal-induced apoptosis at least partially through induction of aB-crystallin. In comparison with Tsc2 À / À MEFs, WT MEFs were more susceptible to serum deprivation (Supplementary Figure 3a) , independent of p53 as both cells are deficient of p53. 17 We knocked down aB-crystallin expression in Tsc2 À / À MEFs and ELT3 cells (p53 þ / þ ) and evaluated the apoptosis induced by serum withdrawal in these cells. Although the basal level of apoptotic cells was higher in non-specific siRNAtransfected cells than in non-transfected cells ( Supplementary  Figures 3b versus 3a) , reduction in aB-crystallin expression sensitized Tsc2 À / À MEFs or ELT3 cells to apoptosis induced by serum withdrawal (Figure 3a and Supplementary Figure 3b) . Therefore, aB-crystallin contributes to resistance to serum deprivationinduced apoptosis in Tsc2-deficient cells with or without p53. As rapamycin or raptor knockdown failed to counteract the apoptotic resistance of Tsc2-null cells to serum limitation, 41 this newly dissected TSC1/2 regulation of apoptosis through mTORC2-NFkB-aB-crystallin signaling cascade may attribute to this phenotype of Tsc2-null cells. Moreover, we identify aB-crystallin as a therapeutic target for induction of cell death in the treatment of TSC.
aB-crystallin is essential for the migration and invasion of TSC1/2 complex-deficient cells TSC1 and TSC2 can inhibit cell migration and invasion in vitro. 42, 43 In our study, Tsc2 À / À MEFs showed an B30-fold increase in transwell migration and an B5-fold increase at invading the ECM gel compared with WT MEFs (Figure 3b ). As both aB-crystallin overexpression and loss of TSC1/2 promote cell migration and invasion, we assumed that loss of TSC1/2 promoted cell migration and invasion at least in part through enhancement of aB-crystallin expression. To test this possibility, aB-crystallin was knocked down in Tsc2 À / À MEFs and ELT3 cells, and the consequent effects on cell migration and invasion were evaluated. Reduction in aB-crystallin expression led to a 440% suppression in transwell migration and a 450% inhibition at invading the ECM gel of Tsc2 À / À MEFs (Figure 3c) . Similarly, reduction in aB-crystallin expression led to a 470% decrease in transwell migration and a 485% decrease at invading the ECM gel of ELT3 cells (Figure 3d ). As metastasis of LAM cells from renal angiomyolipomas to the lungs is a critical step of LAM pathogenesis, aB-crystallin may have a role in dissemination of LAM cells and be a potential target for the treatment of LAM and TSC.
aB-crystallin is required for the proliferation and tumorigenesis of Tsc2-null cells aB-crystallin has been identified as a novel oncoprotein. Thus, mTORC2-mediated upregulation of aB-crystallin might have a crucial role in loss of TSC1/2 complex-induced tumorigenesis. We stably knocked down aB-crystallin in NTC/T2-null cells, which were derived from a subcutaneous tumor formed by Tsc2-null MEFs in a nude mouse (Figure 4a ). 44 Reduction in aB-crystallin expression compromised the proliferation and colony formation of NTC/T2-null cells (Figure 4b and c) . To evaluate the in vivo effect of decreased aB-crystallin expression in NTC/T2-null cells, we examined the tumorigenicity of NTC/T2-null cells expressing shaB-crystallin or shvector in a subcutaneous tumor model in nude mice. Reduction in aB-crystallin expression significantly attenuated the tumorigenesis of NTC/T2-null cells, as assessed by the delayed tumor formation and extended survival of the tumorbearing mice (Figure 4d ). In addition, more apoptotic cells, as revealed by the expression of active (cleaved) caspase-3, were presented in the tumor samples with depleted aB-crystallin expression (Figure 4e ). These data indicate that augmented aB-crystallin could contribute to defective TSC1/2-mediated tumorigenesis and targeting aB-crystallin may help TSC patients. Although encouraging results with rapamycin and its analogs have been seen in the treatment of TSC/LAM, majority of tumors regrew and decline of lung function resumed once the treatment was discontinued. [45] [46] [47] AKT reactivation by disrupting mTOR suppression on AKT may compromise the efficiency of rapamycin, 45, 47 and contributes to its cytostatic effect in suppression of cell proliferation. 48 As inhibition of both mTORC1 and mTORC2 with ATP-competitive inhibitors may associate with broad side effects and the upregulation of aB-crystallin in TSC is mTORC2 dependent, the combinatorial suppression of mTORC1 and aB-crystallin should be applied in the treatment of oncogenic RTK/PI3K/AKT/mTOR signaling propagation-associated TSC/LAM.
